ea0032p831 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013
Lee Misu
, Lupp Amelie
, Gartner Florian
, Castano Justo P
, Schulz Stephan
, Pellegata Natalia
Introduction: Somatostatin analogs (SSAs) are the first-line clinical treatment for patients with pituitary adenomas (PAs) but their efficacy is highly variable among patients. This could be due to a differential expression of somatostatin receptor subtypes (Ssts) among tumors, but this issue is still unresolved. Nonfunctioning pituitary adenomas (NFPAs), which mostly derive from gonadotroph cells, are among the tumors that poorly respond to SSAs. Rats carrying a germline loss...